Andreas Zoephel

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

Frank Hilberg, Gerald J. Roth, Martin Krššák et al. · Cancer Research · 2008 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

Flavio Solca, G. Dahl, Andreas Zoephel et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 867 citations

Medicine, Oncology, Pharmacology +16

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

William Farnaby, Manfred Koegl, Michael J. Roy et al. · Nature Chemical Biology · 2019 · 576 citations · Full text

Life Sciences, Bioinformatics, Oncology +9

Drugging an undruggable pocket on KRAS

Dirk Kessler, Michael Gmachl, Andreas Mantoulidis et al. · Proceedings of the National Academy of Sciences · 2019 · 434 citations · Full text

Medicine, Molecular Biology, Oncology +15

Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor

Laetitia J. Martin, Manfred Koegl, Gerd Bader et al. · Journal of Medicinal Chemistry · 2016 · 224 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +13